Endocrine Therapy of Breast Cancer
Abstract
A recent controversy in the treatment of estrogen receptor positive (ER+) breast cancers is whether an aromatase inhibitor, e.g., letrozole (LET) or TAM should be given as first line endocrine therapy. Unfortunately, response rates are lower, and response durations are shorter, on crossover than when these agents are given as first line therapies, e.g., ~40% of tumors show crossresistance to TAM or an aromatase inhibitor on crossover. Only 50% of ER+ tumors respond to endocrine therapy. Currently, we fail to predict endocrine responsiveness in about 66% of ER+/PgR- (progesterone receptor), 55% of ER-/PgR+, and 25% of ER+/PgR+ tumors. In this new Clinical Translational Research Award, we hypothesize that our analytical methods can extract expression profiles of breast tumors that define their responsiveness (sensitive vs. resistant) to endocrine therapy. These profiles, when combined with known predictive/prognostic factors, will support neural network and biostatistical classifiers or committee machines that predict each tumor's endocrine responsiveness. Our objectives are to array breast cancer cases, build classifiers of endocrine responsiveness (using microarray data), and validate these classifiers in independent data sets. In the long term, we will design custom arrays for use in clinical practice. Genes will be further studied using cellular and molecular methods, and their role as therapeutic targets explored.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2008
- Accession Number
- ADA492475
Entities
People
- Robert Clarke